NEW YORK – Genetron Health said Thursday that it has partnered with Chinese online healthcare firm JD Health to create new solutions for cancer management, focused initially on lung and liver cancer.
Under the agreement, Beijing-based Genetron will work with JD Health, a subsidiary of JD.com, to launch a series of marketing and educational activities for its HCCScreen assay, an early cancer detection blood test for individuals at high risk of developing hepatocellular carcinoma. JD Health’s online network of doctors and retail pharmacies will also gain the option to use Genetron's eight-gene lung cancer mutation assay to inform treatment decisions for non-small cell lung cancer patients.
Financial terms of the agreement were not disclosed.
According to Genetron, the digital health agreement marks its first implementation of a fourth commercialization channel for HCCScreen, joining the hospital, medical exam center, and public health markets.
In a statement, Genetron CEO Sizhen Wang said that the company expects online health services to become a more prominent channel for HCCScreen over time. "More importantly, this will create more value for our society by enabling more patients to access precision oncology products efficiently," he added.